Open AccessIncidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience
Author(s) -
Reyhan Yıldız,
Yavuz Selim Demirel,
Dilşad Mungan,
Ömür Aydın,
Betül Ayşe Sin,
Meltem Ağca,
Sevim Bavbek
Publication year - 2022
Publication title -
tuberkuloz ve toraks
Language(s) - English
Resource type - Journals
ISSN - 0494-1373
DOI - 10.5578/tt.20229702
Subject(s) - omalizumab , medicine , mepolizumab , asthma , incidence (geometry) , atopy , pediatrics , immunoglobulin e , immunology , antibody , eosinophil , physics , optics
To assess the incidence and course of COVID-19 in patients with severe asthma/chronic spontaneous urticaria using biological agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom